• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    2/10/21 11:10:55 AM ET
    $KDMN
    Major Pharmaceuticals
    Health Care
    Get the next $KDMN alert in real time by email
    SC 13G 1 tv01203-kadmonholdingsinc.htm SCHEDULE 13G kadmonholdingsinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934

    Name of issuer:  Kadmon Holdings Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  48283N106

    Date of Event Which Requires Filing of this Statement: December 31, 2020

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  48283N106

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    383,964

    7.  SOLE DISPOSITIVE POWER

    8,468,233

    8.  SHARED DISPOSITIVE POWER

    534,135

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    9,002,368

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    5.25%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Kadmon Holdings Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    450 East 29th Street
    New York, NY 10016

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    48283N106

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

    9,002,368

      (b) Percent of Class:

    5.25%

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  0

    (ii)  shared power to vote or direct to vote:  383,964

    (iii)  sole power to dispose of or to direct the disposition of:  8,468,233

    (iv)  shared power to dispose or to direct the disposition of:  534,135

    Comments:

     

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    Not applicable

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    See Attached Appendix A

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 8, 2021

    By /s/ Christine M. Buchanan
    Name: Christine M. Buchanan
    Title:  Principal

     

     

    Appendix A

    Subsidiary:

    Vanguard Asset Management, Limited

    Vanguard Fiduciary Trust Company

    Vanguard Global Advisors, LLC

    Vanguard Group (Ireland) Limited

    Vanguard Investments Australia Ltd

    Vanguard Investments Canada Inc.

    Vanguard Investments Hong Kong Limited

    Vanguard Investments UK, Limited

    *Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G

     

    Get the next $KDMN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KDMN

    DatePrice TargetRatingAnalyst
    9/14/2021$13.00 → $9.50Buy → Neutral
    Mizuho
    9/9/2021$10.00 → $9.50Buy → Hold
    Jefferies
    7/19/2021$8.00 → $9.00Outperform
    Oppenheimer
    More analyst ratings

    $KDMN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors

      BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Arthur S. Kirsch to the Company's Board of Directors, effective immediately. Mr. Kirsch has decades of experience in investment banking and capital markets, as well as extensive knowledge of the healthcare and life sciences industries. Mr. Kirsch is currently a Senior Advisor with Alvarez & Marsal's Life Sciences Industry Group, and over the course of his 30-year career has held numerous roles in mergers and acqui

      2/24/25 7:00:00 AM ET
      $AVIR
      $LQDA
      $KDMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors

      Collaboration to unlock the therapeutic potential of ROCK2 inhibition for rare neurological diseases Couples Ovid capabilities in rare CNS development with Graviton's expertise in RhoA/ROCK2 signaling pathway to accelerate a series of clinical development programsDevelopment to focus on serious disorders that have few-to-no therapeutic options, including cerebral cavernous malformations and conditions presenting with seizuresOvid to invest $10 million in preferred equity in Graviton and will fund development programsTransaction has no milestone payments and Graviton is eligible for tiered double-digit royalties on commercial sales NEW YORK, May 01, 2023 (GLOBE NEWSWIRE) -

      5/1/23 6:00:00 AM ET
      $MGTX
      $OVID
      $KDMN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Major Pharmaceuticals
    • Kadmon Provides Business Update and Reports Third Quarter 2021 Financial Results

      - REZUROCK™ (belumosudil) 200 mg once daily (QD) tablets are now commercially available for shipment to prescribed patients in the United States -- Execution of strategic launch strategy underway; Third quarter REZUROCK net sales $12.2 million -- Sanofi acquisition of Kadmon expected to close 4Q 2021 -NEW YORK, NY / ACCESSWIRE / November 4, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the third quarter of 2021."The third quarter was an exceptional period for Kadmon culminating in the availability of REZUROCK to patients living with cGVHD and the significant milestones that were achieved in the months following

      11/4/21 8:00:00 AM ET
      $KDMN
      Major Pharmaceuticals
      Health Care

    $KDMN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Kadmon Holdings, Inc.

      SC 13D - Kadmon Holdings, Inc. (0001557142) (Subject)

      9/17/21 8:24:15 AM ET
      $KDMN
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed by Kadmon Holdings, Inc. (Amendment)

      SC 13G/A - Kadmon Holdings, Inc. (0001557142) (Subject)

      5/28/21 5:04:26 PM ET
      $KDMN
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Kadmon Holdings, Inc. (0001557142) (Subject)

      2/17/21 3:12:07 PM ET
      $KDMN
      Major Pharmaceuticals
      Health Care

    $KDMN
    Leadership Updates

    Live Leadership Updates

    See more
    • Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors

      BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Arthur S. Kirsch to the Company's Board of Directors, effective immediately. Mr. Kirsch has decades of experience in investment banking and capital markets, as well as extensive knowledge of the healthcare and life sciences industries. Mr. Kirsch is currently a Senior Advisor with Alvarez & Marsal's Life Sciences Industry Group, and over the course of his 30-year career has held numerous roles in mergers and acqui

      2/24/25 7:00:00 AM ET
      $AVIR
      $LQDA
      $KDMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • Kadmon Announces Appointment of Dr. Simon Cooper as Chief Medical Officer

      NEW YORK, NY / ACCESSWIRE / March 1, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced the appointment of Simon Cooper, MBBS, as Senior Vice President, Chief Medical Officer, effective March 1, 2021. In this role, Dr. Cooper will oversee the Company's medical and clinical activities relating to the potential regulatory approval of belumosudil for chronic graft-versus-host disease and lead the Company's clinical team to advance the development of additional product candidates. Dr. Cooper succeeds John Ryan, M.D., Ph.D., who will remain with the Company and transition to the role of Executive Medical Director, Clinical and Regulatory Development, where he will continue to advise on c

      3/1/21 8:00:00 AM ET
      $KDMN
      Major Pharmaceuticals
      Health Care

    $KDMN
    Financials

    Live finance-specific insights

    See more
    • Kadmon Provides Business Update and Reports Third Quarter 2021 Financial Results

      - REZUROCK™ (belumosudil) 200 mg once daily (QD) tablets are now commercially available for shipment to prescribed patients in the United States -- Execution of strategic launch strategy underway; Third quarter REZUROCK net sales $12.2 million -- Sanofi acquisition of Kadmon expected to close 4Q 2021 -NEW YORK, NY / ACCESSWIRE / November 4, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the third quarter of 2021."The third quarter was an exceptional period for Kadmon culminating in the availability of REZUROCK to patients living with cGVHD and the significant milestones that were achieved in the months following

      11/4/21 8:00:00 AM ET
      $KDMN
      Major Pharmaceuticals
      Health Care
    • Kadmon Provides Business Update and Reports Second Quarter 2021 Financial Results

      NEW YORK, NY / ACCESSWIRE / August 5, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the second quarter of 2021."The recent U.S. FDA approval of REZUROCK marked a transformative event for Kadmon and for patients living with cGVHD. REZUROCK represents a paradigm shift in the cGVHD treatment landscape by uniquely addressing both the immune and fibrotic components of the disease," said Harlan W. Waksal, M.D., President and CEO of Kadmon. "We look forward to bringing this meaningful new therapy to patients in the U.S. by the end of this month."Dr. Waksal added, "Our momentum continues as we advance our portfolio of p

      8/5/21 4:05:00 PM ET
      $KDMN
      Major Pharmaceuticals
      Health Care
    • Kadmon Provides Business Update and Reports First Quarter 2021 Financial Results

      NEW YORK, NY / ACCESSWIRE / May 6, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the first quarter of 2021."We continue to ramp up commercial launch preparation activities for belumosudil in anticipation of the PDUFA goal date of August 30, 2021. Labeling discussions with the FDA are progressing and we believe that belumosudil, if approved, will serve a critical, unmet need for patients with cGVHD," said Harlan W. Waksal, M.D., President and CEO of Kadmon. "In addition, we are exploring the therapeutic potential of belumosudil in systemic sclerosis, a disease with similar manifestations to cGVHD. We continue to

      5/6/21 4:01:00 PM ET
      $KDMN
      Major Pharmaceuticals
      Health Care

    $KDMN
    SEC Filings

    See more
    • SEC Form 15-12B filed by Kadmon Holdings, Inc.

      15-12B - Kadmon Holdings, Inc. (0001557142) (Filer)

      11/19/21 4:01:10 PM ET
      $KDMN
      Major Pharmaceuticals
      Health Care
    • SEC Form EFFECT filed by Kadmon Holdings, Inc.

      EFFECT - Kadmon Holdings, Inc. (0001557142) (Filer)

      11/16/21 12:15:18 AM ET
      $KDMN
      Major Pharmaceuticals
      Health Care
    • SEC Form EFFECT filed by Kadmon Holdings, Inc.

      EFFECT - Kadmon Holdings, Inc. (0001557142) (Filer)

      11/16/21 12:15:09 AM ET
      $KDMN
      Major Pharmaceuticals
      Health Care

    $KDMN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Kadmon Holdings downgraded by Mizuho with a new price target

      Mizuho downgraded Kadmon Holdings from Buy to Neutral and set a new price target of $9.50 from $13.00 previously

      9/14/21 7:13:20 AM ET
      $KDMN
      Major Pharmaceuticals
      Health Care
    • Kadmon Holdings downgraded by Jefferies with a new price target

      Jefferies downgraded Kadmon Holdings from Buy to Hold and set a new price target of $9.50 from $10.00 previously

      9/9/21 5:30:28 AM ET
      $KDMN
      Major Pharmaceuticals
      Health Care
    • Oppenheimer reiterated coverage on Kadmon Holdings with a new price target

      Oppenheimer reiterated coverage of Kadmon Holdings with a rating of Outperform and set a new price target of $9.00 from $8.00 previously

      7/19/21 7:45:32 AM ET
      $KDMN
      Major Pharmaceuticals
      Health Care

    $KDMN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Flowers Cynthia Louise gifted 20,150 shares and returned $103,075 worth of shares to the company (10,850 units at $9.50), closing all direct ownership in the company

      4 - Kadmon Holdings, Inc. (0001557142) (Issuer)

      11/9/21 5:41:38 PM ET
      $KDMN
      Major Pharmaceuticals
      Health Care
    • SEC Form 4 filed by Cohen David E

      4 - Kadmon Holdings, Inc. (0001557142) (Issuer)

      11/9/21 5:37:34 PM ET
      $KDMN
      Major Pharmaceuticals
      Health Care
    • SEC Form 4 filed by Ryan John L

      4 - Kadmon Holdings, Inc. (0001557142) (Issuer)

      11/9/21 5:41:04 PM ET
      $KDMN
      Major Pharmaceuticals
      Health Care